// App-Quantinova.ai

9594 : Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma.

Researchers

Presenter

  • Morganna Louise Freeman

Principal Investigators

  • Alexander Noor Shoushtari

  • Keith A. Betts

  • Komal Gupte-Singh

  • Ella X. Du

  • Corey Ritchings

  • Sumati Rao

Medical Centers

  • The Angeles Clinic and Research Institute, Los Angeles, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Analysis Group, Inc., Los Angeles, CA

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • United States

Companies

  • Analysis Group, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved